1887

Abstract

In a previous vaccination study in cats, the authors reported on accelerated feline immunodeficiency virus (FIV) replication upon challenge in animals vaccinated with a candidate envelope subunit vaccine. Plasma transfer studies as well as antibody profiles in vaccinated cats indicated a causative role for antibodies directed against the hypervariable regions HV3, HV4 and HV5 (HV3–5) of the envelope glycoprotein. The present study was designed to investigate further the contribution of antibodies in envelope vaccine-induced acceleration of FIV infection. To this end, regions HV3–5 of the envelope glycoprotein were deleted from the original vaccine, thus addressing the contributing role of antibodies directed against these hypervariable regions. Interestingly, this approach did not prevent acceleration of challenge infection. Analysis of the antibody responses in the respective groups suggested that removal of HV3–5 redirected the humoral immune response towards other regions of the envelope glycoprotein, indicating that these regions can also induce antibodies that accelerate virus replication.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.79949-0
2004-07-01
2019-11-21
Loading full text...

Full text loading...

/deliver/fulltext/jgv/85/7/vir851833.html?itemId=/content/journal/jgv/10.1099/vir.0.79949-0&mimeType=html&fmt=ahah

References

  1. Bendinelli, M., Pistello, M., Lombardi, S., Poli, A., Garzelli, C., Matteucci, D., Ceccherini-Nelli, L., Malvaldi, G. & Tozzini, F. ( 1995; ). Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen. Clin Microbiol Rev 8, 87–112.
    [Google Scholar]
  2. Boretti, F. S., Leutenegger, C. M., Mislin, C. & 12 other authors ( 2000; ). Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression. AIDS 14, 1749–1757.[CrossRef]
    [Google Scholar]
  3. Boyer, V., Desgranges, C., Trabaud, M. A., Fischer, E. & Kazatchkine, M. D. ( 1991; ). Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion. J Exp Med 173, 1151–1158.[CrossRef]
    [Google Scholar]
  4. de Ronde, A., Stam, J. G., Boers, P. & 8 other authors ( 1994; ). Antibody response in cats to the envelope proteins of feline immunodeficiency virus: identification of an immunodominant neutralization domain. Virology 198, 257–264.[CrossRef]
    [Google Scholar]
  5. Douek, D. C., Brenchley, J. M., Betts, M. R. & 13 other authors ( 2002; ). HIV preferentially infects HIV-specific CD4+ T cells. Nature 417, 95–98.[CrossRef]
    [Google Scholar]
  6. Elyar, J. S., Tellier, M. C., Soos, J. M. & Yamamoto, J. K. ( 1997; ). Perspectives on FIV vaccine development. Vaccine 15, 1437–1444.[CrossRef]
    [Google Scholar]
  7. Finerty, S., Stokes, C. R., Gruffydd-Jones, T. J., Hillman, T. J., Reeves, N. A., Whiting, C. V., Schaaper, W. M., Dalsgaard, K. & Harbour, D. A. ( 2000; ). Mucosal immunization with experimental feline immunodeficiency virus (FIV) vaccines induces both antibody and T cell responses but does not protect against rectal FIV challenge. Vaccine 18, 3254–3265.[CrossRef]
    [Google Scholar]
  8. Finerty, S., Stokes, C. R., Gruffydd-Jones, T. J., Hillman, T. J., Barr, F. J. & Harbour, D. A. ( 2001; ). Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus. Vaccine 20, 49–58.[CrossRef]
    [Google Scholar]
  9. Flynn, J. N., Cannon, C. A., Reid, G., Rigby, M. A., Neil, J. C. & Jarrett, O. ( 1995; ). Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain. Immunology 85, 171–175.
    [Google Scholar]
  10. Garrity, R. R., Rimmelzwaan, G., Minassian, A., Tsai, W. P., Lin, G., de Jong, J. J., Goudsmit, J. & Nara, P. L. ( 1997; ). Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol 159, 279–289.
    [Google Scholar]
  11. Giannecchini, S., Isola, P., Sichi, O., Matteucci, D., Pistello, M., Zaccaro, L., Del Mauro, D. & Bendinelli, M. ( 2002; ). AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts. J Virol 76, 6882–6892.[CrossRef]
    [Google Scholar]
  12. Gonin, P., Fournier, A., Oualikene, W., Moraillon, A. & Eloit, M. ( 1995; ). Immunization trial of cats with a replication-defective adenovirus type 5 expressing the ENV gene of feline immunodeficiency virus. Vet Microbiol 45, 393–401.[CrossRef]
    [Google Scholar]
  13. Hosie, M. J., Osborne, R., Reid, G., Neil, J. C. & Jarrett, O. ( 1992; ). Enhancement after feline immunodeficiency virus vaccination. Vet Immunol Immunopathol 35, 191–197.[CrossRef]
    [Google Scholar]
  14. Huisman, W., Karlas, J. A., Siebelink, K. H., Huisman, R. C., de Ronde, A., Francis, M. J., Rimmelzwaan, G. F. & Osterhaus, A. D. ( 1998; ). Feline immunodeficiency virus subunit vaccines that induce virus neutralising antibodies but no protection against challenge infection. Vaccine 16, 181–187.[CrossRef]
    [Google Scholar]
  15. Karlas, J. A., Siebelink, K. H., Peer, M. A., Huisman, W., Cuisinier, A. M., Rimmelzwaan, G. F. & Osterhaus, A. D. ( 1999; ). Vaccination with experimental feline immunodeficiency virus vaccines, based on autologous infected cells, elicits enhancement of homologous challenge infection. J Gen Virol 80, 761–765.
    [Google Scholar]
  16. Klein, D., Janda, P., Steinborn, R., Muller, M., Salmons, B. & Gunzburg, W. H. ( 1999; ). Provirus load determination of different feline immunodeficiency virus isolates using real-time polymerase chain reaction: influence of mismatches on quantification. Electrophoresis 20, 291–299.[CrossRef]
    [Google Scholar]
  17. Leutenegger, C. M., Hofmann-Lehmann, R., Holznagel, E. & 8 other authors ( 1998; ). Partial protection by vaccination with recombinant feline immunodeficiency virus surface glycoproteins. AIDS Res Hum Retrovir 14, 275–283.[CrossRef]
    [Google Scholar]
  18. Leutenegger, C. M., Klein, D., Hofmann-Lehmann, R., Mislin, C., Hummel, U., Boni, J., Boretti, F., Guenzburg, W. H. & Lutz, H. ( 1999; ). Rapid feline immunodeficiency virus provirus quantitation by polymerase chain reaction using the TaqMan fluorogenic real-time detection system. J Virol Methods 78, 105–116.[CrossRef]
    [Google Scholar]
  19. Leutenegger, C. M., Boretti, F. S., Mislin, C. N. & 10 other authors ( 2000; ). Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif. J Virol 74, 10447–10457.[CrossRef]
    [Google Scholar]
  20. Lombardi, S., Garzelli, C., La Rosa, C., Zaccaro, L., Specter, S., Malvaldi, G., Tozzini, F., Esposito, F. & Bendinelli, M. ( 1993; ). Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope. J Virol 67, 4742–4749.
    [Google Scholar]
  21. Lombardi, S., Garzelli, C., Pistello, M. & 8 other authors ( 1994; ). A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. J Virol 68, 8374–8379.
    [Google Scholar]
  22. Lombardi, S., Massi, C., Tozzini, F., Zaccaro, L., Bazzichi, A., Bandecchi, P., La Rosa, C., Bendinelli, M. & Garzelli, C. ( 1995; ). Epitope mapping of the V3 domain of feline immunodeficiency virus envelope glycoprotein by monoclonal antibodies. J Gen Virol 76, 1893–1899.[CrossRef]
    [Google Scholar]
  23. Lutz, H., Hofmann-Lehmann, R., Bauer-Pham, K. & 8 other authors ( 1995; ). FIV vaccine studies. I. Immune response to recombinant FIV env gene products and outcome after challenge infection. Vet Immunol Immunopathol 46, 103–113.[CrossRef]
    [Google Scholar]
  24. Matteucci, D., Pistello, M., Mazzetti, P., Giannecchini, S., Del Mauro, D., Zaccaro, L., Bandecchi, P., Tozzini, F. & Bendinelli, M. ( 1996; ). Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies. J Virol 70, 617–622.
    [Google Scholar]
  25. Matteucci, D., Pistello, M., Mazzetti, P., Giannecchini, S., Isola, P., Merico, A., Zaccaro, L., Rizzuti, A. & Bendinelli, M. ( 1999; ). AIDS vaccination studies using feline immunodeficiency virus as a model: immunisation with inactivated whole virus suppresses viraemia levels following intravaginal challenge with infected cells but not following intravenous challenge with cell-free virus. Vaccine 18, 119–130.[CrossRef]
    [Google Scholar]
  26. Matteucci, D., Poli, A., Mazzetti, P. & 9 other authors ( 2000; ). Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats. J Virol 74, 10911–10919.[CrossRef]
    [Google Scholar]
  27. Mitchell, W. M., Ding, L. & Gabriel, J. ( 1998; ). Inactivation of a common epitope responsible for the induction of antibody-dependent enhancement of HIV. AIDS 12, 147–156.[CrossRef]
    [Google Scholar]
  28. Pancino, G., Camoin, L. & Sonigo, P. ( 1995; ). Structural analysis of the principal immunodominant domain of the feline immunodeficiency virus transmembrane glycoprotein. J Virol 69, 2110–2118.
    [Google Scholar]
  29. Pedersen, N. C., Ho, E. W., Brown, M. L. & Yamamoto, J. K. ( 1987; ). Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 235, 790–793.[CrossRef]
    [Google Scholar]
  30. Pu, R., Coleman, J., Omori, M., Arai, M., Hohdatsu, T., Huang, C., Tanabe, T. & Yamamoto, J. K. ( 2001; ). Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates. AIDS 15, 1225–1237.[CrossRef]
    [Google Scholar]
  31. Richardson, J., Moraillon, A., Baud, S., Cuisinier, A. M., Sonigo, P. & Pancino, G. ( 1997; ). Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope. J Virol 71, 9640–9649.
    [Google Scholar]
  32. Richardson, J., Moraillon, A., Crespeau, F., Baud, S., Sonigo, P. & Pancino, G. ( 1998; ). Delayed infection after immunization with a peptide from the transmembrane glycoprotein of the feline immunodeficiency virus. J Virol 72, 2406–2415.
    [Google Scholar]
  33. Richardson, J., Broche, S., Baud, S., Leste-Lasserre, T., Femenia, F., Levy, D., Moraillon, A., Pancino, G. & Sonigo, P. ( 2002; ). Lymphoid activation: a confounding factor in AIDS vaccine development? J Gen Virol 83, 2515–2521.
    [Google Scholar]
  34. Rimmelzwaan, G. F., Siebelink, K. H., Huisman, R. C., Moss, B., Francis, M. J. & Osterhaus, A. D. ( 1994; ). Removal of the cleavage site of recombinant feline immunodeficiency virus envelope protein facilitates incorporation of the surface glycoprotein in immune-stimulating complexes. J Gen Virol 75, 2097–2102.[CrossRef]
    [Google Scholar]
  35. Robinson, W. E., Jr, Kawamura, T., Lake, D., Masuho, Y., Mitchell, W. M. & Hersh, E. M. ( 1990; ). Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J Virol 64, 5301–5305.
    [Google Scholar]
  36. Sanders, R. W., Schiffner, L., Master, A., Kajumo, F., Guo, Y., Dragic, T., Moore, J. P. & Binley, J. M. ( 2000; ). Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits. J Virol 74, 5091–5100.[CrossRef]
    [Google Scholar]
  37. Siebelink, C. H., Windrich, R. W., Chu, I., Groen, J., Weijer, K., UytdeHaag, F. G. & Osterhaus, A. D. ( 1990; ). An enzyme linked immunosorbent assay (ELISA) for the detection of feline immunodeficiency virus (FIV) antigen in cell culture and FIV specific antibodies in feline serum. Dev Biol Stand 72, 189–196.
    [Google Scholar]
  38. Siebelink, K. H., Chu, I. H., Rimmelzwaan, G. F., Weijer, K., Osterhaus, A. D. & Bosch, M. L. ( 1992; ). Isolation and partial characterization of infectious molecular clones of feline immunodeficiency virus obtained directly from bone marrow DNA of a naturally infected cat. J Virol 66, 1091–1097.
    [Google Scholar]
  39. Siebelink, K. H., Rimmelzwaan, G. F., Bosch, M. L., Meloen, R. H. & Osterhaus, A. D. ( 1993; ). A single amino acid substitution in hypervariable region 5 of the envelope protein of feline immunodeficiency virus allows escape from virus neutralization. J Virol 67, 2202–2208.
    [Google Scholar]
  40. Siebelink, K. H., Huisman, W., Karlas, J. A., Rimmelzwaan, G. F., Bosch, M. L. & Osterhaus, A. D. ( 1995a; ). Neutralization of feline immunodeficiency virus by polyclonal feline antibody: simultaneous involvement of hypervariable regions 4 and 5 of the surface glycoprotein. J Virol 69, 5124–5127.
    [Google Scholar]
  41. Siebelink, K. H., Karlas, J. A., Rimmelzwaan, G. F., Osterhaus, A. D. & Bosch, M. L. ( 1995b; ). A determinant of feline immunodeficiency virus involved in Crandell feline kidney cell tropism. Vet Immunol Immunopathol 46, 61–69.[CrossRef]
    [Google Scholar]
  42. Siebelink, K. H., Tijhaar, E., Huisman, R. C., Huisman, W., de Ronde, A., Darby, I. H., Francis, M. J., Rimmelzwaan, G. F. & Osterhaus, A. D. ( 1995c; ). Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J Virol 69, 3704–3711.
    [Google Scholar]
  43. Tacnet-Delorme, P., Boyer, V., Thielens, N. M., Hernandez, J. F., Bally, I., Sim, R. B., Desgranges, C. & Arlaud, G. J. ( 1999; ). In vitro analysis of complement-dependent HIV-1 cell infection using a model system. J Immunol 162, 4088–4093.
    [Google Scholar]
  44. Tijhaar, E. J., Huisman, W., Huisman, R. C., Siebelink, K. H., Karlas, J. A., de Ronde, A., van Herwijnen, R., Mooi, F. R. & Osterhaus, A. D. ( 1997; ). Salmonella typhimurium aroA recombinants and immune-stimulating complexes as vaccine candidates for feline immunodeficiency virus. J Gen Virol 78, 3265–3275.
    [Google Scholar]
  45. Uhl, E. W., Heaton-Jones, T. G., Pu, R. & Yamamoto, J. K. ( 2002; ). FIV vaccine development and its importance to veterinary and human medicine: a review. FIV vaccine 2002 update and review. Vet Immunol Immunopathol 90, 113–132.[CrossRef]
    [Google Scholar]
  46. Verschoor, E. J., Boven, L. A., Blaak, H., van Vliet, A. L., Horzinek, M. C. & de Ronde, A. ( 1995; ). A single mutation within the V3 envelope neutralization domain of feline immunodeficiency virus determines its tropism for CRFK cells. J Virol 69, 4752–4757.
    [Google Scholar]
  47. Verschoor, E. J., Willemse, M. J., Stam, J. G. & 7 other authors ( 1996; ). Evaluation of subunit vaccines against feline immunodeficiency virus infection. Vaccine 14, 285–289.[CrossRef]
    [Google Scholar]
  48. Willett, B. J., Flynn, J. N. & Hosie, M. J. ( 1997a; ). FIV infection of the domestic cat: an animal model for AIDS. Immunol Today 18, 182–189.[CrossRef]
    [Google Scholar]
  49. Willett, B. J., Picard, L., Hosie, M. J., Turner, J. D., Adema, K. & Clapham, P. R. ( 1997b; ). Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses. J Virol 71, 6407–6415.
    [Google Scholar]
  50. Wu, S. C., Spouge, J. L., Conley, S. R., Tsai, W. P., Merges, M. J. & Nara, P. L. ( 1995; ). Human plasma enhances the infectivity of primary human immunodeficiency virus type 1 isolates in peripheral blood mononuclear cells and monocyte-derived macrophages. J Virol 69, 6054–6062.
    [Google Scholar]
  51. Yamamoto, J. K., Sparger, E., Ho, E. W., Andersen, P. R., O'Connor, T. P., Mandell, C. P., Lowenstine, L., Munn, R. & Pedersen, N. C. ( 1988; ). Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats. Am J Vet Res 49, 1246–1258.
    [Google Scholar]
  52. Yamamoto, J. K., Okuda, T., Ackley, C. D., Louie, H., Pembroke, E., Zochlinski, H., Munn, R. J. & Gardner, M. B. ( 1991; ). Experimental vaccine protection against feline immunodeficiency virus. AIDS Res Hum Retrovir 7, 911–922.[CrossRef]
    [Google Scholar]
  53. Yamamoto, J. K., Hohdatsu, T., Olmsted, R. A. & 7 other authors ( 1993; ). Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus. J Virol 67, 601–605.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.79949-0
Loading
/content/journal/jgv/10.1099/vir.0.79949-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error